Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021

Rhea-AI Summary

Onconova Therapeutics, Inc. (NASDAQ: ONTX) plans to release its Q1 2021 financial results on May 17, 2021, followed by a conference call at 4:30 p.m. ET. The company is focused on developing novel cancer therapies, including multi-kinase inhibitor ON 123300, which will enter a Phase 1 trial in the U.S. during Q2 2021. Additionally, Onconova is studying oral rigosertib in KRAS+ lung adenocarcinoma. Stakeholders can access the call via phone or through the company's website, where a replay will be available for 90 days.

Positive

• Onconova's multi-kinase inhibitor ON 123300 will enter Phase 1 trials in the U.S. in Q2 2021.
• The company is advancing its oral rigosertib candidate in a study targeting KRAS+ lung adenocarcinoma.

Negative

• None.

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17.

NEWTOWN, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2021 financial results on Monday, May 17, 2021. Management plans to host a conference call and live webcast at 4:30 p.m. ET on that day to discuss these results and provide an update on its pipeline programs.

Conference Call and Webcast Information
Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers and using conference ID 4895447.

Those interested in listening to the conference call via the internet may do so by visiting the investors and media page on the company's website at www.onconova.com and clicking on the webcast link. In addition to the live webcast, a replay will be available on the Onconova website for 90 days following the call.

About Onconova Therapeutics

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China.

Onconova’s product candidate oral rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors
929-469-3859
bmackle@lifesciadvisors.com

FAQ

When will Onconova Therapeutics release its Q1 2021 financial results?

Onconova Therapeutics will release its Q1 2021 financial results on May 17, 2021.

What time is the Onconova conference call scheduled for?

The conference call is scheduled for 4:30 p.m. Eastern Time on May 17, 2021.

What is ON 123300 and when will it enter trials?

ON 123300 is a multi-kinase inhibitor that will begin Phase 1 trials in the U.S. in Q2 2021.

What is the focus of Onconova's research?

Onconova focuses on discovering and developing novel products for cancer treatment.